Table 3. Hazard ratios for prostate cancer in the IMPACT study, (Cox regression analyses) and for breast cancer in the RMH study, (weighted retrospective Cox regression analyses), by BRCA1/2 mutation status.
Cohort | Genetic status | Number with cancer | Number without cancer | HR | 95% CI | P |
IMPACT set | BRCA1 mutation carriers | 5 | 235 | 1.00 | 0.085–11.7 | 0.999 |
BRCA2 mutation carriers | 16 | 191 | 0.493 | 0.103–2.36 | 0.376 | |
All mutation carriers | 21 | 426 | 0.658 | 0.188–2.30 | 0.512 | |
RMH Carrier Clinic Set | BRCA1 mutation carriers | 66 | 65 | 1.063 | 0.448–2.53 | 0.889 |
BRCA2 mutation carriers | 60 | 50 | 0.467 | 0.209–1.04 | 0.063 | |
All mutation carriers | 126 | 115 | 0.782 | 0.449–1.36 | 0.384 |